Key insights
- Personalis (PSNL) secured expanded Medicare coverage for its NeXT Personal cancer test, enabling immunotherapy monitoring for late-stage solid tumor patients. This may improve treatment response assessment and potentially reduce healthcare costs. While positive for PSNL, the broader market impact is limited, primarily benefiting the company's revenue and potentially influencing investor sentiment in the precision oncology space.
FREMONT, Calif. - Personalis Inc. (NASDAQ:PSNL) announced that the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program has expanded coverage for its NeXT Personal minimal residual disease test to include immunotherapy monitoring for patients with late-stage solid tumors.
The coverage determination follows a study published in collaboration with the Vall d’Hebron Institute of Oncology. The study showed the test can evaluate treatment response and predict clinical outcomes in patients undergoing immunotherapy by tracking tumor dynamics.
The NeXT Personal test uses whole-genome sequencing technology to achieve sensitivity down to 1 part per million. The assay tracks up to approximately 1,800 patient-specific mutations to provide molecular profiling of a patient’s tumor.
"Securing Medicare coverage for immunotherapy monitoring across solid tumors is a win for the patients we serve and the fight against cancer," said Chris Hall, Chief Executive Officer of Personalis. "For the first time, Medicare patients on immunotherapy will have an ultrasensitive MRD test to help their doctors see if a treatment is working in real-time."
The company stated that immunotherapy has variable treatment response among patients. The test aims to identify molecular responders and non-responders ahead of traditional radiologic imaging.
Dr. Richard Chen, President and Chief Medical Officer at Personalis, said the VHIO data shows that immunotherapy monitoring with the test can help physicians understand treatment response, including situations where imaging results can be ambiguous.
The information is based on a press release statement from the company. Personalis is a genomics company focused on precision oncology testing and is based in Fremont, California. According to InvestingPro Tips, the company holds more cash than debt on its balance sheet and maintains liquid assets that exceed short-term obligations, providing financial flexibility as it pursues Medicare reimbursement expansion. The company remains unprofitable with revenue of $64.5 million over the last twelve months, though analysts project 13% revenue growth ahead. For deeper insights into PSNL’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.
In other recent news, Personalis Inc. reported its first-quarter 2026 earnings, revealing a mixed financial performance. The company achieved a revenue of $15.47 million, which exceeded analyst expectations of $14.49 million by 6.76%. However, Personalis posted an earnings per share (EPS) of -$0.29, slightly missing the forecast of -$0.27. Additionally, Personalis’s NeXT Personal MRD test showed significant growth, with a 258% year-over-year increase and a 26% rise quarter-over-quarter, reaching over 1,000 oncologists in the first quarter. Analyst firm Needham reiterated a Buy rating with a $12.00 price target, emphasizing the MRD test’s growth. Meanwhile, BTIG maintained a Buy rating but lowered its price target to $11 from $13, citing valuation concerns in the lab sector. These developments reflect the company’s ongoing efforts to expand its market presence and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.